ストックスクリーナーアプリを入手
36.35
4.97%
1.72
プレマーケット:
36.01
-0.34
-0.94%
前日終値:
$34.63
開ける：
$34.86
24時間の取引高:
1.30M
Relative Volume:
1.03
時価総額：
$2.70B
収益：
-
当期純損益:
$-275.16M
株価収益率:
-9.3445
EPS:
-3.89
ネットキャッシュフロー:
$-221.15M
1週間 パフォーマンス:
+11.85%
1か月 パフォーマンス:
+2.14%
6か月 パフォーマンス:
-3.63%
1年 パフォーマンス:
-8.76%
1日の値動き範囲:
$34.63
$37.59
1週間の範囲:
$31.95
$37.59
52週間の値動き範囲:
$28.21
$53.92
Springworks Therapeutics Inc Stock (SWTX) Company Profile
名前
Springworks Therapeutics Inc
セクター
電話
203-883-9490
住所
100 WASHINGTON BOULEVARD, STAMFORD, CT
SWTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SWTX
Springworks Therapeutics Inc
|
36.35 | 2.70B | 0 | -275.16M | -221.15M | -3.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Springworks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-20 | 開始されました | Evercore ISI | Outperform |
| 2024-02-05 | 開始されました | Guggenheim | Buy |
| 2022-12-01 | 開始されました | BofA Securities | Buy |
| 2021-01-19 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-29 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-05 | 開始されました | Barclays | Overweight |
| 2020-03-19 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-01-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2019-10-08 | 開始されました | Cowen | Outperform |
| 2019-10-08 | 開始されました | Goldman | Buy |
| 2019-10-08 | 開始されました | JP Morgan | Overweight |
| 2019-10-08 | 開始されました | Wedbush | Outperform |
すべてを表示
Springworks Therapeutics Inc (SWTX) 最新ニュース
AMI Asset Management Corp Invests $1.44 Million in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Analysts Set SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Target Price at $70.00 - MarketBeat
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Trading Down 6.4%Time to Sell? - MarketBeat
SpringWorks Therapeutics (NASDAQ:SWTX) Trading Up 4.3%Time to Buy? - MarketBeat
Equities Analysts Set Expectations for SWTX FY2024 Earnings - Defense World
SpringWorks Therapeutics' SWOT analysis: biotech stock shows promise amid challenges - MSN
Research Analysts Set Expectations for SWTX FY2024 Earnings - MarketBeat
Equities Analysts Offer Predictions for SWTX FY2027 Earnings - Defense World
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86 - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Gap DownHere's What Happened - MarketBeat
Wedbush Research Analysts Reduce Earnings Estimates for SWTX - MarketBeat
JPMorgan Chase & Co. Lowers Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength? - MSN
SpringWorks Therapeutics (NASDAQ:SWTX) Shares Down 6.4%Time to Sell? - MarketBeat
Items Tagged with 'RPT-04402' - BioWorld Online
Items Tagged with 'SW-3431' - BioWorld Online
Springworks licenses molecular glue targeting PP2A from Rappta - BioWorld Online
Why Springworks Therapeutics Stock is Tumbling - TipRanks
SpringWorks Therapeutics (NASDAQ:SWTX) Given Outperform Rating at Wedbush - Defense World
Wedbush Reiterates "Outperform" Rating for SpringWorks Therapeutics (NASDAQ:SWTX) - MarketBeat
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. - MSN
SpringWorks to Develop Rappta’s First-in-Class Cancer Drug - Contract Pharma
SpringWorks Therapeutics Stock Gets A RS Rating Lift - MSN
SpringWorks Therapeutics Reports Strong 2024 Financial Results - TipRanks
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
SpringWorks Therapeutics Reports Preliminary Fourth Quarter - GlobeNewswire
SpringWorks Therapeutics Hits $172M Revenue in 2024 as OGSIVEO Launch Accelerates Growth - StockTitan
SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate (SWTX) - Seeking Alpha
SpringWorks Therapeutics jumps amid takeover speculation - MSN
Guggenheim Lowers SpringWorks Therapeutics (NASDAQ:SWTX) Price Target to $78.00 - Defense World
SpringWorks Therapeutics price target lowered to $78 from $80 at Guggenheim - Yahoo Finance
Guggenheim Cuts SpringWorks Therapeutics (NASDAQ:SWTX) Price Target to $78.00 - MarketBeat
SpringWorks Therapeutics Trying To Close In On Key Technical Measure - MSN
Guggenheim maintains Buy rating on SpringWorks stock despite minor target adjustment - Investing.com UK
SpringWorks Therapeutics price target lowered to $55 from $58 at BofA - Yahoo Finance
Chief People Officer Pichl Daniel covered exercise/tax liability with 7,269 shares, decreasing direct ownership by 16% to 37,943 units (SEC Form 4) - Quantisnow
SpringWorks Therapeutics (NASDAQ:SWTX) Trading 6.8% HigherTime to Buy? - MarketBeat
Desmoid Tumors Market to Reach New Heights in Growth by 2034, - openPR
SpringWorks Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great - Seeking Alpha
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives $69.50 Consensus Target Price from Brokerages - Defense World
How To Trade (SWTX) - Stock Traders Daily
Ethanol Futures (ZKZ25) Quote - The Globe and Mail
Springworks Therapeutics Inc (SWTX) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):